Combination Chemotherapy in Treating Patients With Metastatic Kidney Cancer
This trial is active, not recruiting.
|Treatments||doxorubicin hydrochloride, ifosfamide|
|Start date||March 1998|
|Trial size||40 participants|
|Trial identifier||NCT00003683, CDR0000066785, EU-98057, FRE-FNCLCC-REINSARDI|
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining doxorubicin and ifosfamide in treating patients who have metastatic kidney cancer.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Avignon, France||Institut Sainte Catherine||no longer recruiting|
|Lyon, France||Centre Leon Berard||no longer recruiting|
|Marseille, France||Institut J. Paoli and I. Calmettes||no longer recruiting|
|Montpellier, France||Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle||no longer recruiting|
|Nantes-Saint Herblain, France||CRLCC Nantes - Atlantique||no longer recruiting|
|Nice, France||Centre Antoine Lacassagne||no longer recruiting|
|Nimes, France||C.H.U. - Hopital Gaston Doumergue||no longer recruiting|
|Paris, France||Institut Curie - Section Medicale||no longer recruiting|
|Paris, France||Hotel Dieu de Paris||no longer recruiting|
|Reims, France||Institut Jean Godinot||no longer recruiting|
|Rennes, France||Centre Eugene Marquis||no longer recruiting|
|Saint Cloud, France||Centre Rene Huguenin||no longer recruiting|
|Saint Nazaire, France||Centre Hospitalier General de Saint Nazaire||no longer recruiting|
|Villejuif, France||Institut Gustave Roussy||no longer recruiting|
Male or female participants at least 18 years old.
DISEASE CHARACTERISTICS: Histologically proven metastatic, sarcomatoid renal cell carcinoma Measurable disease At least 15 mm for pulmonary sites At least 20 mm for other sites No uncontrolled CNS metastases PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-2 Life expectancy: Greater than 3 months Hematopoietic: Neutrophil count greater than 1500/mm3 Platelet count greater than 100,000/mm3 Hemoglobin greater than 9 g/dL Hepatic: Bilirubin less than 1.5 times normal Transaminases less than 2 times normal (less than 4 times normal if due to liver metastases) Renal: Creatinine less than 1.6 mg/dL Creatinine clearance greater than 60 mL/min Other: No contraindication to anthracycline treatment No unstable major organ defect No prior malignancy except basal cell skin cancer or carcinoma in situ of the uterus Not pregnant or nursing Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunotherapy Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified
|Official title||Treatment of Sarcomatous Kidney Cancer That is Metastatic in Adults With Doxorubicin and Ifosfamide. Phase II Study|
|Description||OBJECTIVES: I. Determine the efficacy in terms of objective response after treatment with ifosfamide and doxorubicin in patients with metastatic sarcomatoid renal cell cancer. II. Determine the toxicity of this regimen in these patients. III. Determine the effect of this regimen on the survival of these patients. OUTLINE: This is a multicenter study. Patients receive doxorubicin IV on day 1 and ifosfamide IV over 2 hours on days 1 and 2. Treatment is repeated every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study within 3 years.|
Call for more information